FLGT - Fulgent Genetics awarded CDC contract to study COVID-19 variants

Fulgent Genetics (FLGT) announces that the U.S. Centers for Disease Control and Prevention (“CDC”) has awarded the company a contract to provide genomic sequencing of samples of SARS-CoV-2 on an ongoing basis, leveraging its Next Generation Sequencing (“NGS”) capabilities.Under the agreement, Fulgent Genetics will sequence the genomes of random samples that have tested positive for SARS-CoV-2, the virus that causes COVID-19.Fulgent will leverage its NGS platform and provide sequencing data to the CDC as part of their initiative to conduct a large-scale genomic survey of the virus using random samples from across the United States.CDC believes this large-scale genomic survey can provide important baseline information for national and state-level virus surveillance and help to identify unusual or emerging variants, and ultimately aid in improving the public health response to the virus.

For further details see:

Fulgent Genetics awarded CDC contract to study COVID-19 variants